Evaluating only RxBio’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
RxBio founded at UNC Chapel Hill to develop radiation countermeasures using lipid nanoparticle technology.
FUNDING
$42M Series B raised to advance RBX-001 through FDA Animal Rule approval pathway.
REGULATORY ACTION
FDA feedback indicates RBX-001 preclinical data insufficient for Animal Rule IND progression.
SHUTDOWN
CEO Mackay announces full company shutdown; all 38 employees laid off, assets wound down.
Full Analysis
Free · no account needed
Documented cause
RxBio, a radiopharmaceutical biotech spun out of UNC Chapel Hill, burned through $42M in Series B funding by mid-2023. The company's lead radiation countermeasure candidate RBX-001 failed to demonstrate sufficient efficacy in pivotal preclinical studies required by the FDA's Animal Rule pathway. With no commercial revenue and rising manufacturing costs, CEO Graeme Mackay announced full shutdown in September 2023, laying off all 38 employees.
Lesson
“Animal Rule FDA pathway is high-risk; validate efficacy signals exhaustively before scaling manufacturing spend.”